Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the nutritional effects of a new hydrolyzed rice protein-based infant formula compared to a standard cows milk protein formula in healthy term infants. The study aims to determine if the daily weight gain of infants fed the experimental rice formula for the first four months is not worse than that of infants fed the standard formula. This trial is randomized and quadruple-masked, involving healthy singleton infants born at term with adequate birth weight. Participants are fed exclusively with either the experimental rice-based formula or the control cows milk formula starting from around 7 to 13 days old until they reach 120 days of age. Parents record any deviations from exclusive feeding, including intake of other foods or formulas. The study includes scheduled visits at postnatal days 20, 30, 60, 90, and 120 to monitor feeding, digestive tolerance, behavior, and formula acceptance. During the study, parents also assess their infants quality of life at enrollment and at days 60 and 120. Researchers measure daily weight gain as the primary outcome. The trial includes regular monitoring of feeding patterns and infant well-being through parent diaries and assessments over the four months. Participation lasts from enrollment until the infant reaches 120 days old, with ongoing data collection at specified intervals.
Actively Recruiting
This research aims to better understand hypothalamic obesity HO, a rare form of obesity caused by damage or malfunction in the hypothalamus, which controls energy balance. HO includes cases linked to hypothalamic lesions like craniopharyngioma and genetic causes such as Prader-Willi syndrome or mutations affecting the leptinmelanocortin pathway. HO leads to severe obesity combined with eating disorders, cognitive and behavioral challenges, endocrine and metabolic problems, and sometimes vision loss, greatly impacting quality of life and health outcomes. Currently, no specific treatment exists for HO, and clinical management mainly focuses on behavioral support for eating and physical activity. The study observes two groups one includes adults and children with severe obesity and genetic diagnoses related to eating disorders, and the other includes those with obesity or eating disorders caused by hypothalamic lesions. Participants receive ongoing care and assessments but no experimental drugs or treatments are administered, as this is an observational study. The goal is to improve early diagnosis, understand the natural progression of HO, and identify lifestyle patterns and health markers to personalize future care and guide innovative treatments. Participants will be followed for up to 20 years with regular evaluations occurring every 3 to 5 years depending on age. Assessments include measuring weight, height, calorie intake, eating behaviors such as hyperphagia and binge eating, physical activity, body composition, metabolic and cardiac function, neuropsychological testing, quality of life, and other health parameters. Data collected will help characterize the clinical and genetic profiles of HO to support better diagnosis, prognosis, and future therapeutic approaches.
Actively Recruiting
Healthy Volunteer
Nephronophthisis NPH is a genetic disease caused by mutations in over 20 genes, including NPHP1 and NPHP4. It leads to reduced urine concentration, chronic kidney inflammation, and progresses to kidney failure before age 20. NPH can occur alone or with other symptoms affecting the eyes, brain, skeleton, or organ placement. Currently, there is no effective treatment for NPH or related renal ciliopathies. This research studies therapeutic targets by analyzing proteins and signaling pathways involved in NPH. Approved drugs that correct defects found in cells with NPHP mutations have been identified. Participants include affected patients, healthy relatives, and control groups. Blood and urine samples are collected for multiomics analyses to identify biomarkers and monitor drug responses in kidney cells. Participants provide samples which undergo proteome, miRNAome, and metabolomics profiling. Researchers measure therapeutic targets confirmed in urine-derived kidney cells over three years. The study also collects experimental data from cell models and ranks druggable targets for NPH. This long-term research aims to develop new treatments and biomarkers to improve management of NPH and renal ciliopathies.